Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Julia Asp(Sahlgrenska University Hospital), Lars Palmqvist(Sahlgrenska University Hospital), Björn Andréasson(NU Hospital Group), Johanna Abelsson(NU Hospital Group), Ulrika Hansson(Sahlgrenska University Hospital), Carina Wasslavik(Sahlgrenska University Hospital), Peter Johansson(Linköping University)

Haematologica

January 14, 2016

10.3324/haematol.2015.138958

Cited by 29

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

|Blood|2014|153